Skip to main content
Fig. 2 | Cost Effectiveness and Resource Allocation

Fig. 2

From: Abiraterone acetate and docetaxel with androgen deprivation therapy in high-volume metastatic hormone-sensitive prostate cancer in China: an indirect treatment comparison and cost analysis

Fig. 2

Forest plot for the meta-analysis of combination therapy versus ADT alone with respect to: a overall survival (OS) and b progression-free survival (PFS). Abi abiraterone acetate, CI confidence interval, df degree of freedom, Doc docetaxel, HR hazard ratio, IV instrumental variables, SE standard error

Back to article page

Cost Effectiveness and Resource Allocation

ISSN: 1478-7547

Contact us